Immunotherapy in neoadjuvant setting

Article Properties
Cite
Spisarová, Martina. “Immunotherapy in Neoadjuvant Setting”. Onkologie, vol. 14, no. 5, 2020, pp. 219-20, https://doi.org/10.36290/xon.2020.077.
Spisarová, M. (2020). Immunotherapy in neoadjuvant setting. Onkologie, 14(5), 219-220. https://doi.org/10.36290/xon.2020.077
Spisarová M. Immunotherapy in neoadjuvant setting. Onkologie. 2020;14(5):219-20.
Refrences
Title Journal Journal Categories Citations Publication Date
OpACIN Trial: Neoadjuvant Ipilimumab Plus Nivolumab in Stage III Melanoma, By The ASCO Post 2018
10.1056/NEJMoa1910549
10.1200/JCO.2017.35.15_suppl.506
10.1158/1538-7445.AM2020-3412
OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) Annals of Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 9 2018